Mutant KRAS has been reported in >90% of cases of pancreatic ductal adenocarcinoma [13] and in 30 to 45% of cases of intraductal papillary mucinous neoplasm (IPMN), a pre-malignant distinct pathological entity which is thought to be a precursor of PDAC [14]–[17]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.